Premium
Razoxane regimen for the treatment of psoriasis
Author(s) -
HARPER J.I.,
COPEMAN P.W.M.,
STAUGHTON R.C.D.
Publication year - 1982
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.1982.tb02413.x
Subject(s) - medicine , psoriasis , regimen , dermatology , dermatologic agents , antibiotics , microbiology and biotechnology , biology
Razoxane [ICRF 159, 1,2‐bis(3,5‐dioxopiperazin‐I‐yl) propane] is an oral antimitotic agent, which is very effective in the treatment of psoriasis (Atherton et al ., 1980). Its efficacy in psoriasis. Eight of these were methotrexate 1failures', two had methotrexate‐induced hepatotoxicity and two had not responded to the new aromatic re tinoid, Ro Io‐9359 (Gigason). (Gz) or the early mitotic (M) phase of the cell cycle.